The lack of Canadian capacity to produce COVID-19 vaccines has raised new questions on how governments should approach the pharmaceutical industry. Amid calls for Canada to create a better investment environment for pharmaceutical companies, some are advising caution to avoid overcompensation and a culture that could foster over-prescription, instead suggesting a more results-based approach.
Walter Robinson, a consultant who has spent most of the past 15 years in leadership positions in and around the life sciences sector including at a pharmaceutical trade association, says the vaccine issue is only a symptom of a larger problem.
